The US Food and Drug Administration (FDA) has approved the first aceclidine-based eye drops for the treatment of presbyopia /presbyopia/. Developed by LENZ Therapeutics, VIZZ provides a non-surgical, once-daily solution for blurred near vision associated with aging.
Presbyopia is a common, age-related condition that affects the ability to see up close, usually starting after the age of 45. It affects over 100 million adults in the United States, many of whom rely on reading glasses or contact lenses. VIZZ offers a new non-surgical alternative aimed at those seeking improved near vision without the inconvenience of corrective glasses.
VIZZ's FDA approval is based on data from three studies involving hundreds of participants over 30,000 days of treatment. The trials showed that a single dose improved near vision within 30 minutes, with effects lasting up to 10 hours, and did not compromise distance vision. There were no serious side effects reported, according to the study researchers, and the eye drops were considered well-tolerated.
VIZZ contains aceclidine, which works by gently constricting the pupil to create a pinhole effect that sharpens near vision while preserving distance vision. It is administered as a once-daily prescription eye drop designed to provide fast-acting and long-lasting effects throughout the day. This is the first FDA approval of aceclidine for any ophthalmic use in the United States.
LENZ Therapeutics expects to begin offering samples of VIZZ to U.S. eye care professionals as early as October 2025. Full commercial availability is expected by mid-fourth quarter 2025. The company said VIZZ will be available by prescription nationwide, with marketing activities to begin immediately following approval.